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We have recently found that CD9, a cell surface glycoprotein 
involved in intercellular signaling in hematopoietic cells, is 
also expressed by neurons and glia in the peripheral nervous 
system. Antibody perturbation experiments were conducted 
to examine the function of CD9 in neural cells. Three anti-
CD9 monoclonal antibodies (mAbs) (ROCA 1, ROCA2, B2C11) 
were tested for their ability to promote adhesion of several 
Schwann cell lines (S-16, RN22, JS 1 ), primary Schwann cells 
and PC12 cells. Only B2C11 promotes adhesion in all cells 
tested. Although ROCA2 immunolabels living cells strongly, 
it had no effect on the adhesion of any of these cells. In 
addition, ROCA 1 and several positive-staining, control mAbs 
also had no effect. Another mAb, 192-lgG, directed against 
the low affinity NGF receptor, also promotes the adhesion 
of S-16, PC 12, and primary Schwann cells. In addition to 
adhesion, contact of S-16 Schwann cells with B2C11 spe-
cifically induces morphological changes and robust prolif-
eration. None of the other mAbs, including 192-lgG, induce 
proliferation of S-16 cells. These results provide evidence 
that CD9 may be involved in signaling, activation and growth 
regulation of cells in the nervous system. 
{Key words: CD9, Schwann cells, adhesion, proliferation, 
monoclonal antibody] 
CD9 is a 24-27 kDa cell surface glycoprotein expressed at high 
levels on the surfaces of developing B-lymphocytes, platelets, 
eosinophils, basophils, stimulated T-lymphocytes and certain 
neuroblastoma cell lines (Kersey et al., 1981; Jones et al., 1982; 
Kemshead et al., 1982; Komada et al., 1983; Boucheix et al., 
1987; Boucheix and Benoit, 1988; Von dem Borne et al., 1989). 
This protein is a member of the "tetraspan" family of four 
transmembrane domain-containing proteins that are thought to 
be involved in the regulation of cell growth (Gil et al., 1992). 
Other members of this family are described in an accompanying 
article (Kaprielian et al., 1994). CD9 was purified from human 
platelets (Higashihara et al., 1990; Boucheix et al., 1991; Lanza 
et al., 1991) and its cDNA cloned (Boucheix et al., 1991; Lanza 
et al., 1991 ). Other CD9 homologs were cloned from bovine 
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ocular ciliary epithelial cells (Martin-Alonson et al., 1992), mon-
key kidney (Vero) cells (Mitamura et al., 1992), and from a 
mouse kidney cDNA library (Rubinstein et al., 1993). In a search 
for cell membrane molecules expressed in rostrocaudal gradients 
the PNS, our group identified three mAbs (ROCA 1, ROCA2, 
B2Cl 1) that bind on the surfaces of peripheral glia and neurons 
(Suzue et al., 1990; Kapriclian and Patterson, 1993; Tole and 
Patterson, 1993). We have now identified and cloned the antigen 
for these mAbs as CD9 from rat sciatic nerve (Kaprielian et al., 
1994). 
Perturbation studies using anti-CD9 mAbs and transfections 
have been useful in examining the function of CD9 in hema-
topoietic cells. Anti-CD9 mAbs stimulate fibrin clot retraction 
by fibroblasts (Azzarone et al., 1985), induce homotypic ad-
hesion in pre-B lymphocytes (Masellis-Smith et al., 1990), in-
hibit the motility of lung adenocarcinoma cells (Miyake et al., 
1991 ), augment the adherence of neutrophils to endothelial cells 
(Forsyth, 1991 ), and elicit phosphatidylinositol turnover, phos-
phatidylinositol biosynthesis, and protein-tyrosine phosphory-
lation in human platelets (Yatomi et al., 1993). Transfection of 
CD9 elevates diphtheria toxin receptors on toxin-sensitive cells 
(Mitamura et al., 1992), induces hypersensitivity of mouse cells 
to diphtheria toxin (Brown at al., 1993), and suppresses cell 
motility in several cell lines (Ikeyama et al., 1993). 
Extensive work with human platelets showed that anti-CD9 
mAbs induce activation and aggregation, leading to what is 
termed an adherent phenotype (Jennings et al., 1990; Griffith 
et al., 1991 ). Rather than being directly involved in adhesion, 
it is thought that CD9, together with other proteins, may func-
tion in the initiation of signals leading to cell adhesion. For 
example, an association between CD9 and the integrin GPIIb-
Illa is induced during platelet activation (Slupsky et al., 1989). 
The finding that platelets from patients with Glanzman's throm-
basthenia, which lack this integrin but not CD9, are not acti-
vated by anti-CD9 mAbs further indicates that this CD9-GPIIb-
Illa complex is involved in platelet aggregation (Bouchiex et al., 
1983; Higashihara et al., 1985; Miller et al., 1986). 
Given our localization ofCD9 to peripheral neurons and glia 
(Tole and Patterson 1993; Kaprielian et al., 1994), we asked 
whether CD9 can mediate adhesion and cell growth in neural 
cells. We report here that one anti-CD9 mAb, B2C 11, promotes 
adhesion of a number of Schwann cell lines, PC12 cells and 
primary rat Schwann cells. In addition, this mAb also stimulates 
proliferation of one of the Schwann cell lines. An accompanying 
article further demonstrates that another anti-CD9 mAb en-
hances motility and migration in primary Schwann cells (Anton 
et al., 1994 ). 
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Figure 1. Jmmunodetection of CD9 
and p75 expression in S-16 Schwann 
cell extracts after immunoblotting of I% 
NP-40 supernatant and pellet (SIP) 
fractions. ROCA! , ROCA2, and B2CI I 
specifically recognize the 26 kDa CD9 
band, while the control mAb 192-IgG 
specifically labels the 75 kDa low affin-
ity NGF receptor. Primary antibody 
binding was visualized with a peroxi-
dase-conjugated goat anti-mouse IgG 
secondary antibody. Approximately I 00 
µg of protein was loaded in each lane. 
Materials and Methods 
Antibodies. Monoclonal Abs to rat surface proteins, CD9 (ROCAI , 
ROCA2 and B2Cll), p75LNGFR (192- lgG), Thy- I (OX-7), NGF-induc-
ible large external (NILE) glycoprotein (ASCS4), and a heparan sulfate 
protcoglycan (pg22) have been previously described (Mason and Wil-
liams, 1980; Sweadner, 1983; Akcson and Warren, J 984; Chandler et 
al., 1984; Matthew et al., 1985; Suzue e t al., 1990; Kaprielian and 
Patterson, 1993; Kaprielian et al., 1994). All of these mouse IgG mAbs 
were purified from hybridoma supernatants using the mAb Trap-G kit 
(Pharmacia), and stored at -800C in a solut ion containing I M glycine-
HCI (pH 2.7) and 60 mM Tris-HCI (pH 9) (final pH 7.6). 
Cell culture. The rat Schwann cell line, S-16 (Goda et al., 1991), and 
the rat Schwannomas, RN-22 (Pfeiffer et al., 1978) and JS! (Kimura et 
al. , 1990), were grown in Dulbecco 's modified Eagle's medium (DMEM) 
supplemented with I 0% fetal bovine serum (FBS, Hyclone), glucose 
(7.5%), L-glutamine (50 mM) and penicillin-streptomycin (50 U/ ml and 
50 µglml, respectively) (GIBCO BRL). The rat pheochromocytoma cell 
line, PCI 2 (Greene and Tischler, 1976), was grown on collagen-coated 
tissue culture plates ( IO cm, Falcon) in RPMI 1640 medium supple-
mented with 10% heat-inactivated horse serum, 5% FBS, as well as 
glucose, glutamine, and penicillin-streptomycin, as above. All cell lines 
were maintained at 37°C in a 5% C02• humidified incubator. 
Primary Schwann cells were isolated by collagenase digestion of neo-
natal rat sciatic nerve. Nerves were dissected and desheathed from 12 
rats and then placed in L-15 air medium (Hawrot and Patterson, 1979) 
on ice. Nerves were cut into 2 mm pieces, washed in cold Ca2+/Mga . 
free Hanks' solution, and suspended in 2 ml of collagenase (I mg/ml, 
Worthington; in Ca2+ fMgi+. free Hanks) that had previously been ad-
justed to pH 7 with dilute NaOH. Incubation was at 37°C for 60 min, 
with gentle trituration every 20 min using a fire-polished Pasteur pipette. 
Cells were washed 2 x with L-1 5 air containing I 0% FBS. Undigested 
tissue was removed by a Falcon cell strainer. The yield was approxi-
mately 4 x I 0 ' Schwann cells/ rat. After a final wash in serum-free 
medium t he cells were treated identically to the S-16 cells for use in the 
adhesion assay. 
Cell adhesion assay. Cells were tested for adhesion to mAbs bound 
to nitrocellulose in an assay modified from that of (Lotz et al., 1989). 
Each well of a 96 well plate (Falcon) was coated with 5 liters of a solution 
of 5 cm2 nitrocellulose (Schleicher & Schuell, type BA85) dissolved in 
6 ml of methanol (Lagenaur and Lemmon, 1987), and allowed to dry 
for 15 min in a tissue culture hood. Each purified mAb was dissolved 
at various concentrations in 50 µI of I 00 mM carbonate buffer (pH 9.6), 
and added to the wells. The mAbs were allowed to bind to the nitro-
cellulose for 1-2 hr at RT followed by two washes with Ix phosphate-
buffered saline (PBS). To prevent nonspecific cell binding, the wells were 
then blocked for I hr at 37°C with a 5% BSA solution (in PBS), and 
afterwards washed I x with PBS. For the assay, cells were removed from 
dishes by gently rolling glass beads over the dish, washed in serum-free 
medium, and resuspended in serum-free medium (DMEM, supple-
mented with glucose, L-glutamine and penicillin/streptomycin). To gen-
erate a single cell suspension, the cells were passed through a cell strainer 
(Falcon 2350), counted, and added to the test wells at a density of 5-
10 x JOl cells/well in a volume of 100 µI. The plates were incubated 
at 37°C for 1-2 hr. At the end of the incubation, each test well was filled 
with serum-free DMEM and the entire plate was gently covered with 
an adhesive pressure sensitive film (Falcon 3073). The covered plate 
was then centrifuged upside-down at 500 rpm for 5 min in a Beckman 
J-68 centrifuge (with braking) to remove the unbound cells. The ad-
hesive film and most of the excess medium were then removed gently 
with a multiwell pipetman, leaving behind the adhered cells in 100 µI 
of DMEM. Adherent cells were assayed by the MTS/PMS assay (Barl-
trop et al., 1991). Twenty microliters of a solution containing the te-
trazolium compound [3-(4,5-dimethylthiazol-2- yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS] and an electron 
coupling reagent (phenazine methosulfate, PMS) (CeUTiter 96 AQ,_., 
Pro mega) were added to each well, followed by an incubation of 2-4 hr 
at 37°C. The optical density at 492 nm was determined with an 96 well 
plate reader. These data are expressed as the mean O.D. ± SD of 
triplicate determinations after subtraction of background (no cells add-
ed). 
Cell proliferation assay. Cell proliferation experiments were con-
ducted in plates identical to those used for adhesion measurements. 
Once the unbound cells were removed, the plates were further incubated 
in serum-free medium for 24, 48, or 72 hr. Cell number was then 
determined using the MTS/ PMS solution as described above. 
For the micrographs showing cell proliferation in Figure 9, S-1 6 cells 
were plated on spots of B2C 11 and 192-IgG on 3.5 cm petri dishes 
(Falcon). These dishes were first coated with the nitroceUulose/methanol 
solution and air dried for 15 min at RT. In each dish, 250 ng (in I µI 
of PBS) of mAb were dotted in the center and allowed to adsorb for 1-
2 hr at RT. The dishes were then washed 2 x with PBS and blocked 
with 5% BSA in PBS for I hr at 37°C. Following a wash with PBS, a 
single-cell suspension of S-16 cells in serum-free DMEM was plated at 
a density of 1.25 x 105 cells/dish for the B2Cl I-containing dish and 
2.5 x I 0' for the 192-lgG-containing dish. Cells were allowed to adhere 
for 1.5 hr at 37°C, and unbound cells were removed with two washes 
ofserum-free-DMEM. The same fields were photographed at 2, 24, and 
72 hr. 
Quantitation of immobilized mAb. To determine how well each mAb 
used in the perturbation studies adheres to the culture plate, wells were 
coated with each Ab and the amount of protein was assayed. Duplicate 
wells ofa 96 well plate were coated with 5 µI ofa nitr ocellulose/methanol 
solution and allowed to dry for 15 min at RT. Various amounts of each 
mAb diluted in 50 µI of 100 mM carbonate buffer were added in each 
well and allowed lo adhere for 1-2 hr at RT. The wells were washed 
2 x with PBS to remove the unbound Ab, followed by the addition of 
150 µI of PBS and 150 µI of a 60-C preheated solution of 50: I Reagent 
A and B (BCA protein assay, Pierce). The plate was then incubated at 
60-C for I h r followed by a 15 min cooling period at RT. The optical 

density at 570 nm was determined with a 96 well plate reader. The 
amount of each immobilized Ab was determined by comparing the 
O.D. obtained with those from wells containing known amounts of 
mAb. When 0.5 µ.g, 1 µg, 2.5 µ.g, and 5 µ.g was used, 40%, 28%, 16%, 
and 13%, respectively, was found to adhere on the nitrocellulose/meth-
anol substrate. Very similar results were obtained for all of the mAbs 
used here. 
Immunocytochemistry. S-16 cells were plated on sterile glass cover-
slips inside a six-well dish (Falcon #3046) and grown for 2-3 d. The 
cells were then stained for surface antigens with purified mAbs (20 µg/ 
ml) for 45-60 min at RT. Cells were then washed with culture medium 
and incubated for 30-45 min at RT with fluorescein isothiocyanate 
(FITC) conjugated goat anti-mouse IgG secondary antibody (Hi-F, An-
tibodies Inc.) diluted 1 :200 in serum-containing culture medium. Cells 
were then washed 2 x with culture medium and fixed with 3% form-
aldehyde (diluted in serum-containing culture medium) for 10-15 min 
at RT. Cell-containing coverslips were washed with culture medium 
and mounted on glass slides in glycerol, containing 8 mg/ml n-propyl 
gallate (dissolved in 100 mM Tris-HCI, pH 9). Cells were viewed and 
photographed using an inverted Nikon fluorescence microscope (Dia-
phot 300). 
Protein preparation and immunoblotting. Membrane and cytoskeletal 
fractions were prepared by homogenization and differential centrifu-
gation, as described previously (Kaprielian and Patterson, 1993). De-
tergent-soluble and -insoluble fractions were prepared with 1% NP-40 
as described previously (Kaprielian and Patterson, 1993), as were SDS-
PAGE and immunoblotting procedures. 
Results 
Expression of CD9 in S-16 Schwann cells 
To determine whether CD9 is expressed in S-16 cells, the anti-
CD9 mAbs ROCAl, ROCA2, and B2Cl I were used for im-
munoblotting and immunocytochemistry. All three anti-CD9 
mAbs detected the 26 kDa CD9 band in detergent-soluble (su-
pernatant) but not insoluble (pellet) membrane fractions (Fig. 
l ). A second, minor band at 28 kDa, recognized only by ROCA2 
and B2Cl l, represents a glycosylated form ofCD9 (Kaprielian 
and Patterson, 1993). These mAbs do not bind significantly to 
any other proteins on immunoblots of either detergent-insoluble 
or soluble fractions. These results are consistent with those ob-
tained previously using ROCA 1 and ROCA2 to identify CD9 
in membrane extracts of adult sciatic nerve (Kaprielian and 
Patterson, 1993). As expected, the mAb 192-IgG detected the 
low affinity NGF receptor, p75, exclusively in the supernatant 
fraction (Fig. 1). 
Expression of CD9 on the cell surface was detected by im-
munostaining living S-16 cells using the three anti-CD9 mAbs. 
Strong binding of ROCA2 and B2C 11 on the cell bodies and 
processes of bipolar Schwann cells is illustrated in Figure 2. In 
contrast, ROCA! does not detectably bind the surfaces of these 
cells. In addition, mAb 192-IgG strongly labels the surface of 
S-16 cells (Fig. 2). 
Immobilized antibodies promote adhesion of S-16 cells 
Given that anti-CD9 mAbs can induce an adherent phenotype 
in a variety ofhematopoietic cells, it was logical to ask whether 
the same is true ofSchwann cells, which express significant levels 
of CD9 in vivo and in vitro. In the first experiments, we tested 
the ability of various mAbs to enhance S-16 cell adhesion to 
collagen or fibronectin substrata when the mAbs were added in 
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Figure 3. Adhesion ofS-16 cells to immobilized mAbs; I x 104 cells 
were added to each well of a 96 well plate containing various concen-
trations of each mAb that were immobilized on a nitrocellulose sub-
stratum. Cells were then exposed to the immobilized mAbs in serum-free 
medium for 90 min prior to removal of unbound cells by centrifugation. 
The number of adherent cells was determined spectrophotometrically 
by the MTS/PMS assay. The entire assay is described in detail in ma-
terials and methods. Not shown in graph were the value of cells that 
adhered on 5% BSA (used as a negative control) which was 0.168 ± 
0.033. 
solution, with and without secondary, goat anti-mouse anti-
bodies. We were unable to demonstrate an effect of the three 
anti-CD9 mAbs (ROCA I, ROCA2, and B2Cl 1), or two control 
mAbs, 192-IgG (which labels the surface ofS-16 cells, and thus 
serves as a positive control) and ASCS4 (anti-NILE), (which 
does not stain these cells, negative control) (data not shown). 
In a second set of experiments, adhesion assays were conducted 
with the same mAbs attached to latex beads and covaspheres. 
S-16 cells were incubated with mAb-coated beads or covas-
pheres in solution for 1 hr at RT, and then plated on either 
immobilized fibronectin or tissue culture plastic surfaces. None 
of the mAb-coated beads or covaspheres influences the rate of 
S-16 cell binding to these surfaces (data not shown). 
In contrast, when these mAbs were tested by immobilizing 
them on a nitrocellulose-coated dish surface, a striking enhance-
ment of S-16 cell adhesion is observed on two mAbs. As can 
be seen in Figure 3, B2C 11 and 192-IgG both promote adhesion 
after 90 min of exposure at input mAb concentrations ranging 
from 0.5-10 µglml. Surprisingly, ROCA2 has no effect on cell 
adhesion, despite its strong immunostaining of the cell surface. 
The lack of effect of ROCA2 shows that not all immobilized 
mAbs can influence cell adhesion, and indicates that simple Ab-
antigen binding is not sufficient for adhesion at 500 rpm. The 
ROCA I and ASCS4 mAbs, which do not label these cells, also 
have no effect on cell adhesion. The cells that bind to immo-
Figure 2. Surface immunofluorescence labeling of CD9 and p75 in S-16 cells. Living cells were incubated with purified mAb (20 µ.g/ml) and 
secondary FITC-conjugated, goat anti-mouse lgG secondary Ab, and then fixed as described in Materials and Methods. A and B, Phase and 
fluorescent views of cells stained with secondary mAb. C and D, Phase and fluorescent views of cells stained with ROCA!. E and F, Phase and 
fluorescent views of cells stained with ROCA2. G and H, Phase and fluorescent views of cells stained with B2Cl 1. I and J, Phase and fluorescent 
views of cells stained with 192-IgG. Scale bar, 100 µm. 
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Figure 4. Immobilized B2C 11 induces morphological changes in S-16 
cells. Cells were exposed for 24 hr to either tissue culture plastic in the 
presence of serum containing medium (A), or 5 µglml immobilized 
B2CI I (B) or 192-lgG (C), in serum-free medium. Scale bar, 100 µm. 
bilized B2Cl I and 192-IgG can be distinguished by their mor-
phology; on B2Cl l the cells flatten and spread withiin the first 
30-45 min of contact. As a result, these normally bipolar cells 
(Fig. 4a) resemble flat, polygonal fibroblasts after 24 hr on B2C l 1 
(Fig. 4b). Adhesion of S-1 6 cells to 192-IgG does not induce an 
obvious morphological transformation; the cells remain round-
ed or bipolar (Fig. 4c). 
To determine whether there were any other differences in the 
adhesion ofS-16 cells to immobilized B2Cl 1 and 192-IgG, the 
rate and strength of cell adhesion to Ab-coated dishes was mea-
sured. The rate of adhesion was measured by incubating cells 
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Figure 5. Effects of cytoskeleton-disrupting agents and temperature of 
S-16 adhesion on immobilized 192-lgG and B2Cl I; 1.2 x JO• cells 
were plated on each mAb and allowed to adhere for 90 min in the 
presence of each agent at 37°C, or at the noted temperature before 
removal of unbound cells by centrifugation. The number of bound cells 
was determined spectrophotometrically by the MTS/ PMS assay as de-
scribed in Materials and Methods. Colchicine (JO µM) but not Cyto-
chalasin D (20 µM) disrupts S-16 adhesion on both immobilized mAbs 
at 37°C. Decreasing the temperature also disrupts S-16 adhesion on 
both immobilized mAbs. 
on the mAbs for various times (15, 30, 45, 60, and 90 min) 
followed by removal of nonadherent cells by centrifugation at 
500 rpm (the speed used in the standard adhesion assay). The 
strength of adhesion was measured by incubating cells for 90 
min followed by centrifugation at higher speeds (I 000 and 1500 
rpm). Results from these experiments indicate that initial bind-
ing of S-16 cells to B2Cl I occurs more rapidly and is followed 
by a tighter adhesion in comparison to 192-IgG (data not shown). 
Another comparison involves measuring the affinity of 192-IgG 
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Figure 6. Adhesion of RN22, JS I, and PC 12 cells to immobilized 
mAbs: I x JO• RN22 and JS! cells and 5 x 10' PCl2 cells were added 
to wells containing various concentrations of immobilized mAbs. Cells 
were then incubated in serum-free medium for 90 min, and unbound 
cells removed by centrifugation. The number of adherent cells was 
determined spectrophotometrically by the MTS/PMS assay. Not shown 
in the graphs are the O.D. numbers of cells adhering to 5% BSA (used 
as a negative control): 0.036 ± 0.009 for RN22, 0.065 ± 0.013 for JSI, 
and 0.012 ± 0.038 for PC12 cells. 
for p75, and ROCA2 and B2Cl 1 for CD9 using an ELISA with 
living S-16 cells. In this assay, 192-IgG and B2Cl 1 have a 
similar affinity for the cells, which is twofold higher than that 
of ROCA2 for the same cells (data not shown). 
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Figure 7. Adhesion of primary Schwann cells to immobilized mAbs; 
2 x 104 cells were added to each well of a 96 well plate containing 5 
µ.g/ml of each mAb that was immobilized on a nitrocellulose substratum. 
Cells were then exposed to the immobilized mAbs in serum-free me-
dium for 90 min prior to removal of unbound cells by centrifugation. 
Adherent cells were counted visually. 
The B2Cl 1-induced morphological changes and strong ad-
hesion of S-16 cells suggest that the cytoskeleton and active 
cellular energy might be involved. In order to examine this 
possibility, adhesion assays were carried out at 37°C, in the 
presence of the microfilament inhibitor, cytochalasin D (20 µM), 
or the microtubule inhibitor, colchicine (10 µM). As shown by 
the data in Figure 5, cytochalasin D has no effect on cell ad-
hesion. In contrast, colchicine inhibits adhesion to the B2Cl 1 
and 192-lgG surfaces by approximately 32% and 76%, respec-
tively. Similarly, adhesion ofS-16 cells to immobilized B2Cl 1 
and 192-IgG mAbs is influenced by temperature. S-16 adhesion 
to both mAbs dramatically decreases as the temperature is low-
ered from 37°C to 4°C (Fig. 5). 
Immobilized antibodies promote adhesion of RN22, JS- I, 
PC! 2, and primary Schwann cells 
To test the generality of the effects observed with S-16 cells, we 
tested other glial cell lines derived from peripheral nerve (RN22, 
JS-1 ), the sympathetic neuron-like line, PC 12, as well as dis-
sociated, primary Schwann cells. In addition to B2C 11 and 192-
lgG, two other mAbs that also recognize cell surface antigens 
were used as controls: pg22 (anti-heparan sulfate proteoglycan) 
and OX-7 (anti-Thy-I). The results of adhesion assays using the 
rat Schwannoma cell lines, RN22, JS-1, and the adrenal pheo-
chromocytoma, PC 12, are illustrated in Figure 6. B2C 11 con-
sistently promotes cell adhesion at mAb concentrations of0.5-
10 µg!ml. ROCA2, pg22, and OX-7, mAbs that strongly label 
these cells (data not shown), do not have any effect on adhesion. 
As expected, ROCA 1 and ASCS4, mAbs that do not label these 
cells, also have no effect. 192-IgG, however, strongly promotes 
PC12 cell adhesion (Fig. 6). No morphological changes were 
observed in the RN22, JS-1, and PCI2 cells that adhered to the 
B2Cl I surface. 
The ability of these various mAbs to promote cell adhesion 
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Figure 8. Proliferation ofS-16 cells on immobilized B2Cl I; 2 (open 
symbols) and 5 µ.g/ml (solid symbols) of each mAb was immobilized on 
a nitrocellulose substratum. Cells (I x 104/well) were then exposed to 
the immobilized mAbs in serum-free medium for 90 min followed by 
removal of unbound cells. The number of cells was determined spec-
trophotometrically by the MTS/PMS assay at 1.5, 24, 48, and 72 hr. 
was also tested with primary Schwann cells dissociated from 
neonatal rat sciatic nerve. Schwann cells were identified on the 
basis of their expression of both CD9 and p 7 5LNGFR, as well as 
by their characteristic bipolar morphology (data not shown). 
Results from a 90 min adhesion assay using 5 µ,g/ml of each 
mAb are illustrated in Figure 7. A clear enhancement of cell 
adhesion is seen with B2Cl I and 192-IgG. Some flattening of 
cells on the B2Cl 1 surface was also observed (data not shown). 
Immobilized B2Cl I stimulates proliferation of S-16 Schwann 
cells 
Another function relevant for the potential signaling role for 
CD9 and other members of the "tetraspan" family, is growth 
regulation. Since immobilized B2Cl I and 192-IgG promote 
S-16 cell adhesion, it was possible to compare the ability of 
these two mAbs to influence cell proliferation. The assay was 
carried out in serum-free medium lacking any exogenous growth 
factors or other proteins. Both mAbs were tested at 2 and at 5 
µ,g/ml. Although similar numbers of cells adhere after 90 min 
to both mAbs, only B2CI 1 strongly induces S-16 cells to pro-
liferate for the subsequent 72 hr (Fig. 8). Very slight or no growth 
of S-16 cells results when these cells are plated in serum-free 
medium on tissue culture plastic in the absence of mAb and 
monitored for 3 d (data not shown). 
The striking nature of this proliferative effect is illustrated in 
the photomicrographs in Figure 9. In spots ofimmobilized B2C 11 
and 192-lgG, defined fields of cells were monitored at 2, 24, 
and 72 hr. At 2 hr, a few more cells adhere to B2Cl l than 192-
lgG. By 24 hr, many more flattened cells are present on B2C 11. 
A very clear difference between the cells on these two mAbs 
appears at 72 hr; a monolayer of flat, polygonal S-16 cells was 
generated on B2C 11, in contrast to the few rounded or bipolar 
cells present on 192-IgG. 
Discussion 
CD9 involvement in cell adhesion 
In order to begin to examine the potential functions of CD9 in 
the nervous system, we have carried out antibody perturbation 
experiments with cultured cells. Adhesion and proliferation as-
says were conducted with a number of Schwann cell lines (S-
16, RN22, and JSI), primary Schwann cells, as well as PCl2 
cells. The data reveal that B2Cl I, one of the mAbs against CD9, 
promotes adhesion ofall cells tested. Surprisingly, the p75LNGFR 
mAb, 192-IgG, also promotes cell adhesion. Both of these ad-
hesive effects where demonstrated only when the mAbs were 
immobilized on a nitrocellulose substratum. A possible expla-
nation for the immobilization requirement is that this method 
allows binding to CD9 or p75 at the cell surface without inter-
nalization, thus prolonging the ability of the mAb to maintain 
a sustained activation signal. This hypothesis was also proposed 
to explain the proliferation of human T4 cells in response to 
immobilized anti-CD3 mAb (Geppert and Lipsky, 1987). That 
study also reported that the mAb that stimulates cell prolifer-
ation had no effect when presented to cells in soluble form, as 
was the case in our experiments. 
In contrast to the effects displayed by B2C 11, the other anti-
CD9 mAb, ROCA2, which shows the same affinity to S-16 cells 
as B2C 11 (at 5 µ,g/ml), showed no effect on adhesion. This result 
serves as an important control experiment since it suggests that 
this adhesion assay is not merely measuring Ab-cell binding, 
but rather a possible sequence of downstream events necessary 
for adhesion. Simple Ab-cell binding was not sufficient for cell 
attachment to the nitrocellulose surface after centrifugation at 
500 rpm. Since it is known that the two mAbs (ROCA2 and 
B2Cl l) recognize distinct epitopes on CD9 (Kaprielian et al., 
1994), the effect of B2Cl I on cell adhesion and proliferation 
may depend on stimulation through a particular site on the 
protein. We speculate that the site recognized by B2Cl I is a 
functional epitope and may be a binding site for a natural ligand 
of CD9. In this view, B2Cl l would mimic the effects of the 
natural ligand. In contrast, ROCA2 recognizes a nonfunctional 
epitope and therefore displays no effect. It is possible that the 
slight difference between ROCA2 and B2Cl I in their affinities 
for CD9 may be responsible for their different activating prop-
erties. Differences in affinity, however, will not explain why 
B2Cl l stimulates S-16 cell proliferation while 192-lgG does 
not. Lastly, the third anti-CD9 mAb, ROCA!, does not im-
munolabel living cells and does not show any biological effects. 
We postulate that the ROCA! epitope is blocked on the surface 
of cells tested here as it appears to be in Schwann cells in caudal 
segments of intercostal nerve, satellite cells of caudal sympa-
thetic ganglia and in sciatic nerve (Suzue et al., 1990; Kaprielian 
and Patterson, 1993). This masking would apply only to intact 
cells, however; ROCA I binds to CD9 on immunoblots of all 
of these cells. 
The induction of adhesion by mAb 192-lgG in S-16, PCI 2 
and primary Schwann cells was a surprising finding, since it was 
not known that the low affinity NGF receptor, p75, could play 
a role in cell adhesion. It is hypothesized that p75 functions as 
part of a multimeric complex with the high affinity tyrosine-
kinase receptors (trk oncogenes) to mediate the actions of the 
various neurotrophins (reviewed in Barker and Murphy, 1992). 
Although this may be the primary function of p75, our data 
suggest that it could also play an indirect role in cell adhesion. 
The adhesion ofS-16 cells promoted by B2Cl I and by 192-
B2C11 
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Figure 9. Proliferation ofS-16 cells on immobilized B2CI I. One microliter of each mAb (250 ng) was dotted in the center of a 33 mm petri dish 
on a nitrocellulose substratum. Cells were then expQsed to the immobilized mAbs for 90 min in serum-free medium prior to removal of unbound 
cells. The same fields of cells were then photographed at 2, 24, and 72 hr. Scale bar, I 00 µm. 
IgG is similar in that cells on both mAbs respond in the same 
way to the various treatments applied here (temperature, cy-
tochalasin D, and colchicine). Binding to B2CI 1 and 192-IgG 
can, however, be distinguished by the morphology of the S-16 
cells and the rate and strength of adhesion. Contact ofS-16 cells 
with B2Cl l (unlike 192-lgG) leads to a rapid and tight adhesion, 
followed by striking morphological changes. Consequently, these 
normally bipolar cells resemble fiat, polygonal fibroblasts, prob-
ably as a result of cytoskeletal protein rearrangements. This 
notion is supported by previous studies with immobilized mAbs. 
For example, an immobilized mAb directed against the leu-
kocyte function-associated antigen I (LFA-1) causes a human 
T cell line to develop dendritic processes containing microtu-
bules and intermediate filaments (Kelleher et al. , 1990). An 
immobilized mAb against a novel 20 kDa protein induces both 
cell adhesion and cytoskeleton-dependent morphological changes 
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in a number of T cell lines (Lin et al., 1992). These changes 
include the formation of processes similar to those seen with 
the anti-LFA-1 mAb. 
CD9 involvement in cell growth regulation 
Although both 19 2-IgG and B2C 11 promote cell adhesion, only 
B2Cl l strongly induces proliferation ofS-16 cells in serum-free 
medium, indicating that adhesion does not necessarily lead to 
proliferation. Thus, adhesion and proliferation are separable 
and can be studied independently in this paradigm. It is note-
worthy that the serum-free medium used in these assays was 
not supplemented with any growth factors or other proteins. 
We speculate that the capability of S-16 cells to survive and 
grow under these conditions is due to CD9-stimulated produc-
tion and release of an autocrine growth factor(s). This hypothesis 
is supported by the demonstration that both normal and im-
mortalized Schwann cells can secrete an autocrine growth factor 
that is effective in stimulating their proliferation (Porter et al., 
1987). In addition, it is well established that normal and im-
mortalized Schwann cells produce platelet-derived growth factor 
B-chain, brain-derived neurotrophic factor, Schwannoma-de-
rived growth factor, ciliary neurotrophic factor, NGF (reviewed 
in Eccleston, 1992; LoPachin and Aschner, 1993; Reynolds and 
Woolf, 1993). 
Support for our finding that CD9 is involved in proliferation 
ofSchwann cells comes from previous perturbation experiments 
implicating other members of the tetraspan family (Gil et al., 
1992) in cell growth regulation. For example, mAbs against 
CD37, a human B-lymphocyte-associated antigen, enhance the 
mitogenic effect of anti-immunoglobulin antibodies on B cells 
but inhibit activation induced by anti-CD20 mAbs and B-ccll 
growth factor on the same cells (Ledbetter ct al., 1987). More-
over, a mAb against TAPA-1, a lymphoid cell surface antigen, 
induces antiproliferative effects on numerous human lymphoid 
cell lines (Oren et al., 1990). More recently, a mAb against OX-
44 (the rat homologue of human CD53) was found to be mi-
togenic for primary rat splenic T cells (Bell et al., 1992). Lastly, 
ME49 l, a melanoma-associated antigen that is expressed strongly 
during the early stages of tumor progression, has been suggested 
to serve as a rapid growth inhibitory protein (Hotta et al., 1988). 
In addition to the data on Schwann cell adhesion and prolif-
eration presented in this article, Anton et al. ( 1994) provide 
evidence for CD9 involvement in Schwann cell migration. Taken 
together, these results suggest that CD9 is a multifunctional 
molecule, implicated in a variety of Schwann cell functions in 
vitro. We hypothesize that B2Cl l mimics a natural ligand of 
CD9, and upon binding, exerts its effects by inducing activation 
signals, likely candidates being increased Ca2 + concentration 
and protein phosphorylation (Anton et al., 1994). Since CD9 
protein and mRNA are expressed by peripheral neurons and 
glia in situ (Tole and Patterson, 1993; Kaprielian et al., 1994), 
it is possible that CD9 is a regulator of migration, adhesion, 
and/or growth control in vivo. 
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